Applied Therapeutics (NASDAQ:APLT - Get Free Report) will likely be releasing its Q4 2024 earnings data before the market opens on Thursday, May 8th. Analysts expect Applied Therapeutics to post earnings of ($0.08) per share and revenue of $0.10 million for the quarter.
Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings data on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.61 million. On average, analysts expect Applied Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Applied Therapeutics Price Performance
Shares of Applied Therapeutics stock traded down $0.03 during trading hours on Tuesday, reaching $0.41. The company's stock had a trading volume of 150,366 shares, compared to its average volume of 3,192,359. The firm has a 50 day moving average price of $0.44 and a 200-day moving average price of $2.39. The stock has a market cap of $57.76 million, a P/E ratio of -0.25 and a beta of 2.00. Applied Therapeutics has a one year low of $0.30 and a one year high of $10.62.
About Applied Therapeutics
(
Get Free Report)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
Further Reading
Before you consider Applied Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Applied Therapeutics wasn't on the list.
While Applied Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
